Patentes, regulación de precios e innovación en la industria farmacéutica
AbstractThe trade-off between property rights/price regulation and innovation depends on country characteristics and drug industry specificities. Access to drugs and innovation can be reconciled by seven ways that, among others, include: public health strengthening in the countries with the largest access problems (those among the poor with the weakest institutions); public and private aid to make attractive R&D on neglected diseases; price discrimination with market segmentation; to require patent owners to choose either protection in the rich countries or protection in the poor countries (but not both). Regarding price regulation, after a review of theoretical arguments and empirical evidence, seven strategies to reconcile health and industrial considerations are outlined, including: mitigation of the medical profession dependence on the pharmaceutical industry; consideration of a drug as an input of a production process; split drug authorization from public funding decisions; establish an efficiency minimum for all health production inputs; and stop the European R&D hemorrhagia.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by Department of Economics and Business, Universitat Pompeu Fabra in its series Economics Working Papers with number 754.
Date of creation: May 2004
Date of revision:
Contact details of provider:
Web page: http://www.econ.upf.edu/
I+D farmacéutico; acceso a medicamentos; patentes; regulación de precios; política industrial; política sanitaria;
Other versions of this item:
- Vicente Ortún, 2004. "Patentes, regulación de precios e innovación en la industria farmacéutica," Working Papers, Research Center on Health and Economics 754, Department of Economics and Business, Universitat Pompeu Fabra.
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- D45 - Microeconomics - - Market Structure and Pricing - - - Rationing; Licensing
- P35 - Economic Systems - - Socialist Institutions and Their Transitions - - - Public Finance
- K23 - Law and Economics - - Regulation and Business Law - - - Regulated Industries and Administrative Law
This paper has been announced in the following NEP Reports:
- NEP-ALL-2004-05-26 (All new papers)
- NEP-COM-2004-05-26 (Industrial Competition)
- NEP-EDU-2004-05-26 (Education)
- NEP-MIC-2004-05-26 (Microeconomics)
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
- Danzon, Patricia M. & Towse, Adrian, 2003. "Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents," Working paper 258, Regulation2point0.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-57, October.
If references are entirely missing, you can add them using this form.